Plasmid DNA Manufacturing Market Growth, Size, Trends Analysis - By Disease, By Grade, By Application, By Development Phase - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Plasmid DNA Manufacturing Market Introduction and Overview

According to SPER market research, 'Plasmid DNA Manufacturing Market Size- By Disease, By Grade, By Application, By Development Phase - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Plasmid DNA Manufacturing Market is predicted to reach 16.07 billion by 2034 with a CAGR of 21.67%.

Plasmids are small, circular DNA molecules found in bacteria and other microscopic creatures. Plasmids are physically distinct from chromosomal DNA and reproduce independently. They typically have a small number of genes, particularly those related with antibiotic resistance, that are transferred from one cell to the next. Plasmid DNA can be utilized directly as therapeutic agents in gene therapy and vaccine antigen synthesis, or indirectly in a range of research applications, such as using plasmid DNA as a critical starting material for transient transfection.

Restraints: Plasmid manufacture presents a number of obstacles, including low yield, plasmid instability, and regulatory considerations, all of which demand specialized facilities and adherence to good manufacturing standards (GMP). As a result, a rising number of academics and drug developers are turning to contract service providers with specialized skills and modern technology to meet their GMP plasmid production needs.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Disease, By Grade, By Application, By Development Phase.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Charles River Laboratories, VGXI, Inc, Danaher (Aldevron), Kaneka Corp, Nature Technology, Cell and Gene Therapy Catapult, Eurofins Genomics, Lonza, Luminous BioSciences, LLC, Akron Biotech. and others.

Plasmid DNA Manufacturing Market Segmentation:

By Disease: Based on the Disease, Global Plasmid DNA Manufacturing Market is segmented as; Infectious Disease, Cancer, Genetic Disorder, Others.

By Grade: Based on the Grade, Global Plasmid DNA Manufacturing Market is segmented as; R&D Grade, GMP Grade.

By Application: Based on the Application, Global Plasmid DNA Manufacturing Market is segmented as; DNA Vaccines, Cell & Gene Therapy, Immunotherapy, Others.

By Development Phase: Based on the Development Phase, Global Plasmid DNA Manufacturing Market is segmented as; Pre-Clinical Therapeutics, Clinical Therapeutics, Marketed Therapeutics.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA2547

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Plasmid DNA Manufacturing Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Plasmid DNA Manufacturing Market

7. Global Plasmid DNA Manufacturing Market, By Disease (USD Million) 2021-2034

7.1. Infectious Disease
7.2. Cancer
7.3. Genetic Disorder
7.4. Others

8. Global Plasmid DNA Manufacturing Market, By Grade (USD Million) 2021-2034

8.1. R&D Grade
- 8.1.1. Viral Vector Development
- 8.1.2. mRNA Development
- 8.1.3. Antibody Development
- 8.1.4. DNA Vaccine Development
- 8.1.5. Others
8.2. GMP Grade

9. Global Plasmid DNA Manufacturing Market, By Application (USD Million) 2021-2034

9.1. DNA Vaccines
9.2. Cell & Gene Therapy
9.3. Immunotherapy
9.4. Others

10. Global Plasmid DNA Manufacturing Market, By Development Phase (USD Million) 2021-2034

10.1. Pre-Clinical Therapeutics
10.2. Clinical Therapeutics
10.3. Marketed Therapeutics

11. Global Plasmid DNA Manufacturing Market, (USD Million) 2021-2034

11.1. Global Plasmid DNA Manufacturing Market Size and Market Share

12. Global Plasmid DNA Manufacturing Market, By Region, (USD Million) 2021-2034

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America

13. Company Profile

13.1. Charles River Laboratories
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. VGXI Inc
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Danaher (Aldevron)
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Kaneka Corp
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Nature Technology
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Cell and Gene Therapy Catapult
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Eurofins Genomics
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Lonza
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Luminous BioSciences, LLC
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Akron Biotech
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Others